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Acute respiratory viral diseases, like most other infectious
diseases, affect mainly infants and young children, who
present with 6-8 episodes per year and usually develop more
severe manifestations than in adults. It is well-documented
that innate antiviral immune responses in early life are
characterized by lower type I interferon (IFN) responses (1)
and reduced natural killer cell activity, which despite their
higher numbers exhibit lower cytotoxic capacity and reduced
number of cytoplasmic granules and degranulation ability
(2). Additionally, lower cytotoxic T lymphocyte activity and
numbers of effector and memory CD8+ T cells have also
been described at younger ages (3).
Most data indicate a significant role for innate immunity
and T-cell cytotoxicity in the control of viral infections.
Surprisingly, however, as seen in the severe acute respiratory
syndrome-related coronavirus (SARS-CoV) (4) and Middle
East respiratory syndrome-related coronavirus (MERS) (5)
outbreaks, the current SARS-CoV-2 pandemic shows low
morbidity and near-absent mortality in previously healthy
children. On February 28, 2020, in one of the first publica-
tions on the clinical features of SARS-CoV-2 infection, Guan
et al. (6) analyzed 1,099 laboratory-confirmed patients from
Wuhan, China. Among these, only nine were under 14 years
(0.9%) and only one had a severe course. Shortly thereafter, a
review of 72,314 cases, conducted by the Chinese National
Center for Disease Control and Prevention, showed that less
than 1% of cases were in children under 10 years of age (7).
Similarly, reports from Italy, Brazil, and the USA confirm a
lower incidence of serious infections among younger indi-
viduals (8-10).
In late March 2020, the Chinese Center for Disease Con-
trol and Prevention reported the epidemiological character-
istics of a nationwide case series of 2,143 pediatric patients
(o18 years old) with COVID-19, including 731 laboratory-
confirmed cases and 1,412 suspected patients (11). Among
the confirmed cases, 12.9% were asymptomatic, and sympto-
matic disease was mild in 43.1%, moderate in 41%, and
severe in 2.5% of cases. Only 0.4% (3 patients) were classified
as critical. Considering the available data for the whole
series, the most severe cases were more frequent among
those under 5 years old. Clinical data for 171 confirmed cases
(1 day to 15 years old) from the Wuhan Children’s Hospital
were described in more detail (12). Like in adults, there was a
predominance of males (60.8%), and the clinical manifesta-
tions were quite similar: fever was present in 41.5% of
the children and adolescents at any time during the illness,
and other common features were cough and pharyngeal
erythema. Pneumonia was diagnosed in 111 patients (64.9%),
33 (19.3%) presented only upper respiratory tract manifesta-
tions, and 27 (15.8%) had asymptomatic infection. Bilateral
ground-glass opacities were the most common radiologic
finding, observed in 32.7% of the cases. Three patients
required intensive care support and invasive mechanical
ventilation (1.75%). These patients had co-existing morbidities
(hydronephrosis, leukemia in maintenance chemotherapy, and
bowel intussusception), and the only death in the series
occurred in a 10-month-old patient with intussusception.
As with SARS-CoV, COVID-19 is believed to be initiated
by the binding of the SARS-CoV-2 envelope-anchored spike
protein to the outer surface of the angiotensin-converting
enzyme 2 (ACE2) catalytic domain (13), promoting endocy-
tosis where viral and host membranes fuse and consequent
entry of the virus into the host cell. Angiotensin-converting
enzyme (ACE) and its later described homolog ACE2 are
critical proteases for regulating the renin-angiotensin sys-
tem (RAS), exerting opposite roles. Whereas ACE generates
angiotensin II, promoting vasoconstriction, ACE2 cleaves
angiotensin II to generate Ang1–7, which acts as a negative
regulator and exerts an antihypertensive effect (14,15). Zhao
et al. (16) reported that ACE2 pulmonary expression is
concentrated mainly in type II alveolar cells, which express
many other genes that could favor viral replication, thus
offering an explanation for the severe alveolar damage
associated with SARS-CoV-2 infection. However, one should
remember that, in addition to the lung, ACE2 is highly
expressed in the kidneys, heart, and testes and is expressed
at a lower level in the colon and liver (17). Furthermore,
ACE2 may not be the only cellular receptor for the virus.
Infection of T lymphocytes, which express very low levels
of ACE2, has been described and attributed to the binding
of the virus spike protein to CD147, another cell surface
molecule (18).
Nevertheless, considering ACE2 as the main gate for
infection, the first hypothesis for the diminished suscept-
ibility of children to SARS-CoV-2 suggests a different ACE2
configuration, concentration, or binding capacity or a lessDOI: 10.6061/clinics/2020/e1947
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harmful alveolar epithelial cell response to ACE2 in children
when compared with that in adults (19). Although attractive
and supported by observations that some comorbidities
associated with a more severe evolution of COVID-19 may
be also associated with modifications of ACE2 expression
(20-23), the role of ACE2 modulation in this infection is
far from clear. Reports suggesting a protective role against
severe COVID-19 by increased ACE2 expression are paral-
leled by others that indicate otherwise (24). In agreement
with the hypothesis that ACE2 expression levels have a
significant role in acute respiratory distress syndrome (ARDS),
which also occurs in COVID-19, an experimental mouse
model of H5N1 virus-induced lung injury and death showed
ACE2 downregulation following infection (25). In this context,
however, one should add a confounding observation: arterial
hypertension, a condition that is associated with modified
ACE2 expression (26) and was one of the main comorbidities
in the Chinese population with severe COVID-19, is barely
present among the first North American series reported by
the CDC (27). However, it is possible that the increased repre-
sentation of male individuals among patients with confirmed
COVID-19 might be because of decreased ACE2 expression
caused by testosterone in contrast to the enhancement caused
by estrogens (28,29), a phenomenon that, although not
explored in children, might take part in their relative
resistance.
Finally, a recently released news report of a fatal case of
COVID-19 in a 3-month-old infant with Bartter’s syndrome
has indicated that ACE2 does have a significant role in
COVID-19. This is an interesting example of how rare genetic
disorders may contribute to understanding the pathophy-
siology of common diseases: patients affected with this
autosomal recessive tubulopathy have increased ACE2 levels
and elevated renin and aldosterone levels (30). However,
how these factors actually interact in the case of a SARS-CoV-
2 infection remains to be determined.
The aforementioned suggestion by Fang and Luo (19)
that the intracellular response induced by ACE2 is different
in children than in adults, especially in the elderly, leads
us to another hypothesis. In animal models, as age increases,
there is a shift in the balance between the pulmonary
RAS enzymes, ACE and ACE2. As ACE levels increase, so
do the angiotensin II levels, leading to more intense
inflammation and increased lung injury (31). Although
the same ACE/ACE2 imbalance was not observed in
humans in a later study by the same group (32), the inci-
dence, susceptibility, course, and mortality from ARDS
do tend to increase progressively with age (33-35). It is
well-known that aging is associated with a process called
immunosenescence, that is, the decline in the efficiency of
the immune systems with age (36). Increasing age is asso-
ciated with increased neutrophil elastase activity, primary
granule release, inaccurate migration, and increased oxida-
tive stress, leading to a state of systemic inflammation (37)
with impaired repair mechanisms, thus contributing to exag-
gerated responses and tissue injury in the elderly (35). In
contrast, could the relative resistance of children be due to an
immature immune system?
Unlike other respiratory viruses, such as influenza, res-
piratory syncytial virus, adenovirus, and others, one very
intriguing aspect is that the current SARS-CoV-2 pandemic
(like with SARS-CoV and MERS) may not cause a more
serious illness in immunosuppressed patients in addition to
being milder in immature hosts. In a recent letter from a
pediatric liver transplantation unit in Bergamo, Italy, D’Antiga
(38) noted that there were no cases of ARDS in patients
immunosuppressed because of transplantation, chemotherapy,
or other immunosuppressive treatments. However, some of
these cases were positive for SARS-CoV-2, suggesting that
immunosuppressed patients may not be at higher risk of
severe pulmonary disease compared with the general popula-
tion. Nevertheless, this is still purely observational, as is a
report of fatal COVID-19 pneumonia in two transplanted
patients in China (39). Additionally, another Italian study
reported 4% of adults with chronic arthritis diseases under
immunosuppressive treatment had suspected or confirmed
COVID-19, with no deaths (40).
This brings us to what may prove to be the crucial point
in understanding COVID-19 pathophysiology. As in most
(if not all) infectious diseases, this disease is not a direct and
simple result of the infection, but the consequence of both
the presence of the pathogen and its interaction with the
patient’s immune system. Thus, even if we unveil, as we are
indeed unveiling, many characteristics of the virus that
contribute to and are coherent with the clinical manifesta-
tions and course of COVID-19 without adding to the picture
the immune reaction to the virus, we will be missing the
target. In addition, by taking into account the immune
response, we need to consider that the response in a patient
will not be independent of the individual immunological
history, where previous infections and momentary immune
status will drive the response to one pattern or another and,
possibly, to different clinical evolutions of the disease.
Currently, however, we are only beginning to describe the
immune response of patients to SARS-CoV-2, and we are
unclear about the most effective immune response pattern
against the virus. A prospective observation of a 47-year-old
female patient with mild-to-moderate COVID-19 showed
increased numbers of antibody-secreting cells, follicular
helper T cells, activated CD4+ T cells and CD8+ T cells, as
well as antiviral IgM and IgG antibodies in blood before
symptomatic recovery (41). This study indicates that early
robust adaptive immune responses were elicited against
SARS-CoV-2, as should occur in other viral diseases, but
we cannot conclude from it whether humoral or cellular
responses are more relevant. In contrast, patients who had
recovered from SARS showed potent antibody responses
specific to the SARS-CoV spike protein with robust neu-
tralizing activity, which persisted at high titers over a three-
year follow-up (42). In addition, the IgG level in patients
with mild SARS-CoV infection was significantly higher than
that in patients with severe infection (43).
If the antibody response is responsible for the severity of
COVID-19, we should consider that adults would have come
into contact with and have produced antibody responses
against several antigens from related viruses throughout
their lives on a much larger scale than in children (44). These
antibodies could cross-react with SARS-CoV-2 with a low
affinity and could induce activation of an inflammatory
response, either by local deposition of immune complexes or
by binding to Fc receptors present on pulmonary antigen-
presenting cells, instead of promoting an effective viral
neutralization. In fact, in patients with COVID-19, the innate
immune response shows an increase in neutrophil numbers
and C-reactive protein (CRP), D-dimer, and IL-6 levels (43,45).
Another possible mechanism through which antibodies
could contribute to the severity of the disease is the antibody-
dependent enhancement, which is well-described in dengue
2
Why is SARS-CoV-2 infection milder among children?
Palmeira P et al.
CLINICS 2020;75:e1947
virus infections (46). This was also, in fact, demonstrated by
Yip et al. (47) in SARS-CoV infection of human macrophages
in vitro. Nevertheless, although murine anti-spike antibodies
facilitated human macrophage infection via the Fcg receptor
II (CD32), this resulted in neither SARS-CoV replication nor
alteration of pro-inflammatory cytokine/chemokine produc-
tion or apoptosis-induced ligands by these infected cells.
This is relevant because other clinical studies indicate that
COVID-19 patients have lymphocytopenia with high levels
of several cytokines and chemokines, such as G-CSF, IP-10,
MCP-1, MIP-1a, and TNF-a (48,49). Therefore, the increased
production of pro-inflammatory cytokines could be the cause
of both viral sepsis and damage to tissues or organs,
resulting in septic shock, disseminated intravascular coagu-
lation, and multi-organ dysfunction syndrome. These phe-
nomena of a cytokine storm syndrome in COVID-19 are
similar to those in hemophagocytic lymphohistiocytosis (50)
and in the macrophage activation syndrome associated with
systemic-onset juvenile idiopathic arthritis or juvenile sys-
temic lupus erythematosus (51-53), indicating that COVID-19
is, at least in some cases, a disease of immune dysregulation.
Another observation deserves to be highlighted: in the
description of the clinical characteristics of coronavirus
disease in China, lymphocytopenia (o1.2 109 per liter)
was present in only 3.5% of pediatric patients in contrast to
83.2% of the 1,099 patients of all age groups analyzed (6). The
characteristically higher numbers of total lymphocytes and
their main subpopulations in healthy infants and young
children (54) attracts attention and warrants further investi-
gations, although we cannot determine whether this lack of
lymphocytopenia is a cause or consequence of a diminished
disease severity.
Another hypothesis related to the immune history of
patients has been proposed, that is, a ‘‘protective’’ effect of
BCG (Bacille Calmette-Guérin) vaccination against tubercu-
losis, as countries where BCG is compulsorily administra-
ted in the first few days of life, like Brazil, have a seemingly
more controlled dissemination of the SARS-CoV-2 virus (55).
A recent review discussed the possible non-specific mechan-
isms of action of BCG or muramyl dipeptide (MDP) against
viral infections in animal models and humans (56). The
proposed mechanisms were an induction of CD4 and CD8
T-cell responses, mainly of the Th1 and Th17 subtypes, to
secondary unrelated viruses (57); an increased functional
cross-reactive antibody response (58); and increased produc-
tion of pro-inflammatory cytokines, such as IL-1b and TNF-
a, by epigenetic reprogramming of monocytes and macro-
phages (‘‘trained immunity’’), probably as a consequence
of greater activation of CD11b, TLR4, and CD14 on these
cells (59,60). Faced with a disease where most pathogenetic
mechanisms seem to rely on ‘‘excessive’’ immune responses,
these hypotheses would have to be adjusted before one could
incorporate them into the picture of the natural history of
COVID-19.
As is evident, the pathophysiology of SARS-CoV-2 infec-
tion is far from being understood. Most data indicate that it
is, in fact, a multisystemic disease and not only a respiratory
disorder. Hematologic, cardiac, renal, neurologic, gastroin-
testinal, and other alterations are being described as parts
of a conundrum that needs to be clarified. Understanding
the reasons for the consistent observations that immune-
immature and some immunosuppressed hosts are spared
from severe manifestations could contribute to elucidating
COVID-19 aggression mechanisms and indicate pathways
to offer better and more efficient treatment to infected
patients. Interestingly, after the acceptance of this manu-
script, there have been warnings from pediatric associations
in Spain, the UK and the USA about cases of children with
confirmed COVID-19. These patients developed septic
shock and Kawasaki-like features, after initial gastrointest-
inal manifestations and without flu-like symptoms (61).
It is noteworthy that vascular lesions and dysregulated
inflammatory responses, which seem to be characteristics of
COVID-19 in adults, may also occur in children.
On the last April 27th, Bi et al. (62) published a retro-
spective cohort study from Shenzhen, China demonstrating
that the rate of infection in children below 10 years was
similar to the population average, although children are less
likely to develop severe symptoms.
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